Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X...

Related Keywords

Georgia ,United States ,Austria ,Atlanta ,London ,City Of ,United Kingdom ,Vienna ,Wien ,Brian Johnston Lynn Lewis ,J Thorac Cardiovasc ,Coll Cardiol ,D Ashley Lee ,International Normalized Ratio ,Gilmartin Group ,Drug Administration ,European Association For Cardio ,Artivion Inc ,Prnewswire Artivion Inc ,Late Breaking Science Presented ,European Association ,Cardio Thoracic Surgery Annual Meeting ,Onx Aortic Heart Valve Low ,Late Breaking Science ,Cardio Thoracic Surgery ,Annual Meeting ,Onx Aortic Valve ,Clinical Lead ,Aortovascular Surgery ,Barts Heart Centre ,Real World Experience ,Low Dose ,Onx Aortic Low ,Onx Aortic Prosthetic Valve ,Ashley Lee ,Artivion ,Nc ,